Dihydropyrimidinase‑related protein 5 controls glioblastoma stem cell characteristics as a biomarker of proneural‑subtype glioblastoma stem cells

Park,Min Gi; Seo,Sunyoung; Ham,Seok Won; Choi,Sang‑Hun; Kim,Hyunggee

doi:10.3892/ol.2020.11668

Dihydropyrimidinase‑related protein 5 controls glioblastoma stem cell characteristics as a biomarker of proneural‑subtype glioblastoma stem cells

Authors:
- Min Gi Park
- Sunyoung Seo
- Seok Won Ham
- Sang‑Hun Choi
- Hyunggee Kim
View Affiliations

Affiliations: Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea
Published online on: May 22, 2020 https://doi.org/10.3892/ol.2020.11668
Pages: 1153-1162
Copyright: © Park et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma (GBM) is the most aggressive and malignant brain tumor, resulting in a poor prognosis. The current therapy for GBM consists in concurrent radiation and chemotherapy following removal of the tumor. Although the therapy prolongs patient survival, recurrence often occurs. The major cause of tumor recurrence is thought to be GBM stem cells (GSCs), which aid the development of chemo‑radiotherapy resistance, and can self‑renew and aberrantly differentiate. Therefore, GSCs should be targeted to eradicate the tumor and prevent recurrence. Transcriptomic analysis has categorized GBM into proneural (PN), mesenchymal and classical subtypes, and the outcome of recurrence and prognosis markedly depends on subtype. To identify specific GSC markers, the present study analyzed public microarray and RNA‑seq data and identified dihydropyrimidinase‑related protein 5 (DRP5) as a candidate GSC marker. DRP5 is known to mediate semaphorin 3A signaling and is involved in the regulation of neurite outgrowth and axon guidance during neuronal development. In the present study, DRP5 was specifically upregulated in the PN‑subtype GSCs and served crucial roles in maintaining GSC properties, including tumor sphere formation, stem cell marker expression and xenograft tumor growth. Furthermore, bioinformatics analysis revealed that DRP5 expression was positively correlated with signatures of stemness, including Notch, Hedgehog and Wnt/β‑catenin expression, which are also known to be positively correlated with PN‑subtype gene signatures. Conversely, DRP5 expression was negatively correlated with NF‑κB and signal transducer and activator of transcription 3 stemness signatures, which are negatively correlated with PN‑subtype gene signatures. Taken together, these findings suggested that DRP5 was specifically expressed in PN‑subtype GSCs and may be used as a functional marker of PN‑subtype GSCs.

View Figures

View References

1	Mazaris P, Hong X, Altshuler D, Schultz L, Poisson LM, Jain R, Mikkelsen T, Rosenblum M and Kalkanis S: Key determinants of short-term and long-term glioblastoma survival: A 14-year retrospective study of patients from the Hermelin Brain Tumor Center at Henry Ford Hospital. Clin Neurol Neurosurg. 120:103–112. 2014. View Article : Google Scholar : PubMed/NCBI
2	Porter KR, McCarthy BJ, Freels S, Kim Y and Davis FG: Prevalence estimates for primary brain tumors in the United States by age, gender, behavior and histology. Neuro Oncol. 12:520–527. 2010. View Article : Google Scholar : PubMed/NCBI
3	Omuro A and DeAngelis LM: Glioblastoma and other malignant gliomas: A clinical review. JAMA. 310:1842–1850. 2013. View Article : Google Scholar : PubMed/NCBI
4	Dobelbower MC, Burnett Iii OL, Nordal RA, Nabors LB, Hyatt MD and Fiveash JB: Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. J Med Imaging Radiat Oncol. 55:77–81. 2011. View Article : Google Scholar : PubMed/NCBI
5	Neman J and Jandial R: Decreasing glioma recurrence through adjuvant cancer stem cell inhibition. Biologics. 4:157–162. 2010.PubMed/NCBI
6	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
7	Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL and Rich JN: Cancer stem cells in glioblastoma. Genes Dev. 29:1203–1217. 2015. View Article : Google Scholar : PubMed/NCBI
8	Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG and Parada LF: A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 488:522–526. 2012. View Article : Google Scholar : PubMed/NCBI
9	Xie Q, Mittal S and Berens ME: Targeting adaptive glioblastoma: An overview of proliferation an invasion. Neuro Oncol. 16:1575–1584. 2014. View Article : Google Scholar : PubMed/NCBI
10	Kanabur P, Guo S, Simonds GR, Kelly DF, Gourdie RG, Verbridge SS and Sheng Z: Patient-derived glioblastoma stem cells respond differentially to targeted therapies. Oncotarget. 7:86406–86419. 2016. View Article : Google Scholar : PubMed/NCBI
11	Jackson M, Hassiotou F and Nowak A: Glioblastoma stem-like cells: At the root of tumor recurrence and a therapeutic target. Carcinogenesis. 36:177–185. 2015. View Article : Google Scholar : PubMed/NCBI
12	Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, et al: Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 32:42–56.e6. 2017. View Article : Google Scholar : PubMed/NCBI
13	Schmidt EF and Strittmatter SM: The CRMP family of proteins and their role in Sema3A signaling. Adv Exp Med Biol. 600:1–11. 2007. View Article : Google Scholar : PubMed/NCBI
14	Quach TT, Honnorat J, Kolattukudy PE, Khanna R and Duchemin AM: CRMPs: Critical molecules for neurite morphogenesis and neuropsychiatric diseases. Mol Psychiatry. 20:1037–1045. 2015. View Article : Google Scholar : PubMed/NCBI
15	Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N and Honnorat J: Collapsin response mediator proteins (CRMPs): Involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol. 28:51–64. 2003. View Article : Google Scholar : PubMed/NCBI
16	Tan F, Thiele CJ and Li Z: Collapsin response mediator proteins: Potential diagnostic and prognostic biomarkers in cancers (Review). Oncol Lett. 7:1333–1340. 2014. View Article : Google Scholar : PubMed/NCBI
17	Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, et al: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun. 9:4762018. View Article : Google Scholar : PubMed/NCBI
18	Yang Y, Jiang Y, Xie D, Liu M, Song N, Zhu J, Fan J and Zhu C: Inhibition of cell-adhesion protein DPYSL3 promotes metastasis of lung cancer. Respir Res. 19:412018. View Article : Google Scholar : PubMed/NCBI
19	Nagano H, Hashimoto N, Nakayama A, Suzuki S, Miyabayashi Y, Yamato A, Higuchi S, Fujimoto M, Sakuma I, Beppu M, et al: p53-inducible DPYSL4 associates with mitochondrial supercomplexes and regulates energy metabolism in adipocytes and cancer cells. Proc Natl Acad Sci USA. 115:8370–8375. 2018. View Article : Google Scholar : PubMed/NCBI
20	Moutal A, Honnorat J, Massoma P, Desormeaux P, Bertrand C, Malleval C, Watrin C, Chounlamountri N, Mayeur ME, Besancon R, et al: CRMP5 controls glioblastoma cell proliferation and survival through Notch-dependent signaling. Cancer Res. 75:3519–3528. 2015. View Article : Google Scholar : PubMed/NCBI
21	Wang L, Liu W, Tang H, Xie X, Zou C, Wang Y, Gao Z and Yin J: DRP5 is involved in cancer cell growth and predicts poor prognosis in human osteosarcoma. Cancer Med. 6:982–993. 2017. View Article : Google Scholar : PubMed/NCBI
22	Dubey D, Lennon VA, Gadoth A, Pittock SJ, Flanagan EP, Schmeling JE, McKeon A and Klein CJ: Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology. 90:e103–e110. 2018. View Article : Google Scholar : PubMed/NCBI
23	Petit V, Massonnet G, Maciorowski Z, Touhami J, Thuleau A, Nemati F, Laval J, Cahteau-Joubert S, Servely JL, Vallerand D, et al: Optimization of tumor xenograft dissociation for the profiling of cell surface markers and nutrient transporters. Lab Invest. 93:611–621. 2013. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al: Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 9:391–403. 2006. View Article : Google Scholar : PubMed/NCBI
26	Mao P, Joshi K, Li J, Kim SH, Li P, Santana-Santos L, Luthra S, Chandran UR, Benos PV, Smith L, et al: Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA. 110:8644–8649. 2013. View Article : Google Scholar : PubMed/NCBI
27	Brot S, Malleval C, Benetollo C, Auger C, Meyronet D, Rogemond V, Honnorat J and Moradi-Ameli M: Identification of a new CRMP5 isoform present in the nucleus of cancer cells and enhancing their proliferation. Exp Cell Res. 319:588–599. 2013. View Article : Google Scholar : PubMed/NCBI
28	Tan M, Cha C, Ye Y, Zhang J, Li S, Wu F, Gong S and Guo G: CRMP4 and CRMP2 interact to coordinate cytoskeleton dynamics, regulating growth cone development and axon elongation. Neural Plast. 2015:9474232015. View Article : Google Scholar : PubMed/NCBI
29	Ponnusamy R and Lohkamp B: Insights into the oligomerization of CRMPs: Crystal structure of human collapsin response mediator protein 5. J Neurochem. 125:855–868. 2013. View Article : Google Scholar : PubMed/NCBI
30	Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, et al: Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell. 24:331–346. 2013. View Article : Google Scholar : PubMed/NCBI
31	Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, et al: The transcriptional network for mesenchymal transformation of brain tumours. Nature. 463:318–325. 2010. View Article : Google Scholar : PubMed/NCBI
32	Barbato L, Bocchetti M, Di Biase A and Regad T: Cancer stem cells and targeting strategies. Cells. 8:E9262019. View Article : Google Scholar : PubMed/NCBI
33	Kwon SM, Kang SH, Park CK, Jung S, Park ES, Lee JS, Kim SH and Woo HG: Recurrent glioblastomas reveal molecular subtypes associated with mechanistic implications of drug-resistance. PLoS One. 10:e01405282015. View Article : Google Scholar : PubMed/NCBI
34	Dagogo-Jack I and Shaw AT: Tumor heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 15:81–94. 2018. View Article : Google Scholar : PubMed/NCBI
35	Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, et al: Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 344:1396–1401. 2014. View Article : Google Scholar : PubMed/NCBI
36	Dai X, Liao K, Zhuang Z, Chen B, Zhou Z, Zhou S, Lin G, Zhang F, Lin Y, Miao Y, et al: AHIF promotes glioblastoma progression and radioresistance via exosomes. Int J Oncol. 54:261–270. 2019.PubMed/NCBI
37	Qian Z, Ren L, Wu D, Yang X, Zhou Z, Nie Q, Jiang G, Xue S, Weng W, Qiu Y and Lin Y: Overexpression of FoxO3a is associated with glioblastoma progression and predicts poor patient prognosis. Int J Cancer. 140:2792–2804. 2017. View Article : Google Scholar : PubMed/NCBI
38	Luo K and Zhuang K: High expression of PCBP2 is associated with proression and poor prognosis in patients with glioblastoma. Biomed Pharmacother. 94:659–665. 2017. View Article : Google Scholar : PubMed/NCBI
39	Martínez-Murillo R and Martínez A: Standardization of an orthotopic mouse brain tumor model following transplantation of CT-2A astrocytoma cells. Histol Histopathol. 22:1309–1326. 2007.PubMed/NCBI
40	Huang YH, Ning ZJ and Huang CY: Crystal structure of dihydropyrimidinase in complex with anticancer drug 5-fluorouracil. Biochem Biophys Res Commun. 519:160–165. 2019. View Article : Google Scholar : PubMed/NCBI
41	Fukada M, Watakabe I, Yuasa-Kawada J, Kawachi H, Kuroiwa A, Matsuda A and Noda M: Molecular characterization of CRMP5, a novel member of the collapsin response mediator protein family. J Biol Chem. 275:37957–37965. 2000. View Article : Google Scholar : PubMed/NCBI